West Paces Advisors’s Repligen RGEN Stock Holding History

West Paces Advisors’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-39	Closed	-$7.17K	–	589
2024 Q1	$7.17K	Hold	39	–	–	﹤0.01%	383
2023 Q4	$7.01K	Buy	+39	New	+$6.07K	﹤0.01%	392

Other funds holding RGEN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

West Paces Advisors's RGEN Position: Q2 2024 in Review

West Paces Advisors sold out of Repligen (RGEN) in Q2 2024, closing a stake of 39 shares — an estimated $7.17K sold.

West Paces Advisors first reported a position in RGEN in Q4 2023 and held it in 2 quarters. The position peaked at $7.17K in Q1 2024. 455 funds tracked by Wall St. Rank hold RGEN as of Q2 2024.

West Paces Advisors reported no remaining Repligen position as of Q2 2024 after selling out during the quarter.
West Paces Advisors sold 39 Repligen shares in Q2 2024, an estimated $7.17K.
West Paces Advisors first reported a position in Repligen in Q4 2023 and held it in 2 quarters.
West Paces Advisors's Repligen position peaked at $7.17K in Q1 2024.
455 funds tracked by Wall St. Rank held Repligen as of Q2 2024.

Based on West Paces Advisors's 13F filing for Q2 2024, filed 17 Jul 2024.